The microbiome-mitochondria axis: the context-dependent role of urolithin A in aging and cancer via mitophagy.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic preclinical literature and early human trials
PubMed 42550351 · doi:10.1007/s11033-026-12542-y
What was done
This narrative review synthesized published evidence regarding urolithin A (UA), a gut microbiota-derived metabolite of dietary ellagitannins and ellagic acid. The authors reviewed microbial metabolism, metabotypes (UM-A, UM-B, UM-0), pharmacokinetic exposure, mitophagy biology (such as PINK1/Parkin, TFEB, AMPK, sirtuin, and Nrf2 pathways), aging phenotypes, and cancer models.
What was found
The abstract reports no quantitative values or statistical metrics. Preclinical work associates UA with enhanced mitochondrial turnover and altered inflammatory signaling via mitophagy-related pathways. Human evidence is restricted to short trials measuring safety, muscle performance, mitochondrial signatures, and circulating biomarkers. In oncology, data stem mostly from cellular and animal studies showing that mitophagy can limit early cellular damage but may also promote tumor survival during metabolic and therapeutic stress.
Why it matters
The paper clarifies that urolithin A exerts context-dependent mitochondrial effects rather than straightforward anti-aging or anticancer benefits, urging caution against premature therapeutic claims.
Limits
The abstract describes a narrative review without systematic search criteria or meta-analytic data. Human trials are limited to short-term surrogate endpoints, cancer claims rely almost entirely on non-human models, and the abstract provides no sample sizes or effect sizes.
Cited by
- supports Urolithin A is a metabolite produced by the gut microbiome from dietary polyphenols and ellagitannins found in foods like pomegranates.